Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0 or stage IB - III hormone receptor negative breast cancer
Percentage of female patients, age >= 18 and < 70 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC stage T1cN0M0 or Stage IB - IIIC, whose primary tumor is of the breast, and progesterone and estrogen receptor negative is recommended or administered multi-agent chemotherapy within 4 months (120 days) of diagnosis
Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis
Denominator
1.15 Denominator
Include if all of the following characteristics are identified: Women Age 18-69 at time of diagnosis Known or assumed first or only cancer diagnosis Epithelial malignancy only Primary tumors of the breast Invasive tumors Surgical procedure of primary site AJCC T1cN0M0, or AJCC Stage IB to IIIC Primary tumor is estrogen receptor negative and progesterone receptor negative All or part of first course of treatment performed at the reporting facility Known to be alive within 4 months (120 days) of diagnosis
Exclusions
Exclusions
Exclude, if any of the following characteristics are identified: Men Age < 18 and >= 70 Not the first or only cancer diagnosis Tumor not originating in the breast Non-epithelial malignancies, exclude 8200 - adenoid cystic carcinoma and rare tumors (8940 - Mixed tumor, malignant, NOS; 8950 - Mullerian mixed tumor; 8980 – Carcinosarcoma; 8981 - Carcinosarcoma, embryonal) Non-invasive tumors ER positive PR positive Evidence of in situ or metastatic disease None of 1st course therapy performed at reporting facility No surgical procedure of the primary site Died within 4 months (120 days) of diagnosis Participation in a clinical trial which directly impacts the delivery of the standard of care Not AJCC T1cN0M0 or not AJCC Stage IB-IIIC
Measure Record
Most Recent Endorsement Activity
Measure Retired and Endorsement Removed Cancer Spring Cycle 2020
Public Comments